SynthesisInternational journal of molecular sciences2026
GLP-1 Receptor Agonist Therapy in Patients with Cancer: A Review of Clinical Outcomes.
Synthesis in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for the management of obesity and type 2 diabetes, including among patients with cancer. Although previous research has mainly focused on cancer incidence, their associations with clinical outcomes after cancer diagnosis remain less well characterized. Therefore, the present study aimed to evaluate the oncologic and survival outcomes associated with GLP-1 RA use in adults with an established malignancy. We performed a systematic review of comparative studies evaluating GLP-1 RA use in patients with a confirmed cancer diagnosis. PubMed, Scopus and Web of Science were searched for English-language publications from 1 January 2016 to 8 August 2026. Twenty-six retrospective cohort studies were included in the qualitative synthesis. Thirteen studies included selective GLP-1 RAs and tirzepatide within the same exposure group. Study quality was assessed using the Newcastle-Ottawa Scale. Twenty-five studies evaluated overall survival and/or all-cause mortality, while nine assessed cancer recurrence, progression, or related outcomes. Survival and mortality outcomes more often favored the exposed group (especially compared with nonuse) than not, but findings were less consistent in active-comparator analyses. Evidence for recurrence and progression was sparse and heterogeneous, and no clear signal of increased risk was observed. Because all of these were observational studies with substantial differences in populations, comparators, exposure definitions, and duration of follow-up, the survival associations do not imply causality or direct antitumor effects of GLP-1 RAs. Clinically, the preponderance of evidence does not support the use of GLP-1 RAs as cancer-directed therapy, and their use in patients with cancer should be guided by established indications such as obesity and type 2 diabetes. Potential explanations include effects on glycemic and cardiovascular risk factors, treatment selection, residual confounding, or combinations thereof. Prospective studies and randomized controlled trials with cancer-specific outcomes and longer follow-up are needed to further evaluate these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.